Eli Lilly (LLY) announced the launch of 7.5 mg and 10 mg Zepbound single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. Lilly also reduced the price of the 2.5 mg and 5 mg vials. These new offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions. Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Amgen (NASDAQ:AMGN) to Invest $200M in India High Tech Site as Trump Tariffs Loom
- Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
- Eli Lilly’s (NYSE:LLY) Future Takes Aim at Big Problems in Plain Sight
- Walmart reports Q4 beat, Salesforce in cloud talks with Microsoft: Morning Buzz
- Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports